Amwell reported a first-quarter 2026 net loss of $10.3 million on revenue of $54.9 million [2], [3].
These results reflect the company's ongoing effort to stabilize its financial position after a period of volatility in the telehealth sector. Achieving cash-flow breakeven is critical for the firm to sustain its operations without relying on further external funding.
The company reported an adjusted EBITDA loss between $12 million and $16 million [1]. While the firm continues to face challenges, the current net loss is a decrease from the $18.4 million net loss reported in the first quarter of 2025 [2]. However, revenue for the period declined by 18 percent year-over-year [2].
Amwell is focusing on consolidating its platform to better serve the needs of payers, and providers [4], [5]. The company aims to reach positive cash flow from operations by the fourth quarter of 2026 [1], [5].
"Over the past 12 months, we focus on what matters most, solving clear urgent customer needs," Dr. Ido Schoenberg, Chairman and CEO, said [1].
Chief Financial Officer Mark Hirschhorn said the company is making progress toward its financial targets. "We have increased confidence that we will meet our long-term goal of achieving positive cash flow from operations in the fourth quarter," Hirschhorn said [6].
The company's strategy involves streamlining its service offerings to reduce overhead while attempting to maintain its market share in the competitive U.S. health-technology landscape.
“Amwell reported a first-quarter 2026 net loss of $10.3 million on revenue of $54.9 million.”
Amwell's financial trajectory shows a narrowing net loss, but the 18 percent drop in revenue indicates a struggle to grow its top line in a post-pandemic market. The company's ability to hit the Q4 2026 cash-flow breakeven target will determine if its current consolidation strategy is sufficient to offset the decline in revenue and stabilize the business for the long term.
